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Introduction
Photodynamic Therapy (PDT) is a non-thermal technique for inducing tissue damage with light following administration of a light-activated photosensitising drug which can be selectively retained in malignant or diseased lesions relative to normal adjacent tissue (1) (2, 3) . In recent years, 5-aminolaevulinic acid (ALA)-mediated PDT has become one of the most promising fields in PDT research. ALA is the prodrug of the photosensitiser protoporphyrin IX (PpIX). After ALA administration, cells generate PpIX through the haem biosynthetic pathway. Clinically, when sufficient intracellular levels of PpIX are attained following either topical or oral ALA administration, the targeted tissue is irradiated with visible light to activate the sensitizer leading to generation of cytotoxic species and ultimately cell death. At a molecular level, this involves the interaction of the excited photosensitiser with molecular oxygen, leading to the generation of electrophilic species (singlet oxygen and/or radicals) that cause oxidative damage to cellular constituents such as phospholipidic membranes, nucleic acids, and proteins (4).
The main advantage of ALA-induced PpIX relative to other photosensitisers is the short half-life of its photosensitising effects, which do not last longer than 48 h (5) . Moreover, ALA also has great potential as a photodiagnostic or photodetection agent in clinical practice. The use of ALA-induced PpIX fluorescence is currently being exploited for diagnosis of bladder cancer, and intraepithelial lesions of the cervix, lung and brain cancer (6, 7, 8, 9, 10) . Although ALA-PDT has already shown great potential both for the treatment of cancer and infectious diseases (10, 11) , its efficacy is somewhat limited by the hydrophilic nature of the molecule, leading to poor penetration through certain malignant tissues. At physiological pH, ALA is a zwitterion, which severely impairs its ability to cross cell membranes via passive uptake, and may result in poor penetration and nonhomogeneous distribution in target tissues (12) . In addition, saturation of heme synthesis as well as photobleaching of PpIX are also factors limiting the outcome of ALA-PDT (13, 14) . To address these issues, a variety of ALA prodrugs have been investigated, incorporating specific chemical modifications that may provide enhanced uptake and hence higher PpIX production and thus photosensitisation (13) . The conversion of ALA to ester prodrugs with enhanced lipophilicity has been extensively investigated, and various studies have demonstrated that esterification of ALA with both aliphatic linear and cyclic alcohols reduces the amount of ALA required for photosensitisation (14, 15, 16, 17, 18) . Prodrugs of this kind, in particular methyl (Me-ALA) and hexyl ester (He-ALA) derivatives of ALA, have now been validated in a clinical setting, with regulatory approval being granted for the use of Me-ALA for the treatment of actinic keratosis in Europe and USA (19, 20) , and basal cell carcinoma in Europe (20) . He-ALA has also been approved in Europe for its use in fluorescence cystoscopy (21) .
Other chemical approaches to enhance ALA-PDT have focused on increasing the payload of ALA that may be delivered by a single prodrug entity, as well as combining ALA administration with the use of other molecules that may boost PpIX production, by blocking downstream ferrochelatase-catalysed conversion of PpIX to haem. In the latter case, various iron chelators (22, 23, 24, 25) and chemotherapeutic agents (26) have been shown to be effective in enhancing levels of PpIX production upon administration of ALA. The use of ALA conjugated to first or second-generation dendrimers also results in enhanced porphyrin synthesis with such prodrugs at low concentrations compared to an equivalent dose of ALA itself (27, 28, 29, 30 ).
An attractive way to obtain ALA prodrugs that have both improved physicochemical properties and can selectively release ALA in specific cell lines, is to incorporate ALA into a short peptide derivative (31, 32, 33, 34) .
Upon cellular uptake, ALA release may be mediated by the action of cytoplasmic esterases and/or proteases. Following this approach, Giuntini et al (35) synthesized a range of ALA dipeptide derivatives that are uncharged at physiological pH, and are more lipophilic than ALA, yet retain adequate aqueous solubility. They are also stable at physiological pH, unlike ALA and its esters. The general structure of these compounds is shown in Figure 1 , and they were demonstrated to be incorporated into the immortalized PAM212 cell line with significantly greater efficiency than ALA itself.
Significantly, the efficiency of uptake of any given prodrug was not directly correlated with downstream PpIX production, showing that ALA release was mediated by a specific protease activity. Indeed, prodrugs containing a D-amino acid component are incorporated but not processed, while in cell lines such as A549 epithelial carcinoma that have a low expression of acyl-peptide hydrolase (a protease shown to release ALA from these compounds (36), efficient prodrug uptake, but low ALA release and PpIX production was observed. These encouraging in vitro results and studies in skin explant models (37) highlight the possibility to design peptide prodrugs of this type that can be used to target disease-specific levels of a given enzymatic activity to provide selective ALA release. In this context, it is important to evaluate the most promising of these prototypes in clinically relevant cancer cell lines and in vivo to assess the real potential of this novel strategy for ALA-PDT.
As shown in Figure 1 , the ALA residue is conjugated with an amino acid via a peptide linkage and on the other side through an ester linkage, which are then cleaved enzymatically within the cells to liberate ALA. Importantly, the peptide is N-acetyl terminated. Such molecules are stable at physiological pH, unlike ALA, its esters, and dipeptide derivatives with a free amino terminus, but they may be fine-tuned in terms of their overall lipophilicity to favor passive uptake while still retaining water solubility, by variation of R′ (the side chain of the amino acid coupled to ALA) and the ester moiety R (35) . We studied a set of dipeptide compounds and selected those which exhibited significantly enhanced phototoxicity in cells compared to ALA. Those results showed that water-soluble peptide prodrugs of ALA can greatly increase its cellular uptake, generating more intracellular PpIX and improving tumour cell photosensitization.
Moreover, they are not cytotoxic and are stable at physiological pH (37) .
The aim of the present work was to investigate in vivo the properties of two ALA dipeptide prodrugs, N-acetyl terminated leucinyl (AcLeuALAMe) and phenylalanyl-ALA (AcPheALAMe), which have previously been shown to exhibit significantly enhanced cellular uptake and PpIX-induced phototoxicity compared to ALA. We employed the keratinocyte normal/tumour cell line pair PAM212 and PAM212-Ras as an in vitro model, and the mammary carcinoma cell line LM2 as an in vivo model of a subcutaneous transplantable tumour. One day after PDT, mice were sacrificed and samples of tumours with their adjacent SOTs were excised, extended, sliced, fixed in 10% buffered formalin, embedded in paraffin, sectioned, stained with haematoxylin and eosin and examined by light microscopy under ×10 and ×40 magnifications employing a BX51 Olympus microscope, and photographs were documented with a Q-color 5 camera. and PAM212-Ras cells for each pro-photosensitiser, LD50s were calculated from the light dose response curves using using a three parameter logistic equation (GraphPad Prism, San Diego, CA, U.S.A.). LD50 values were calculated as the geometric mean ± 95% confidence intervals of the log-transformed curves. Statistical comparisons between LDs were made using the Student's t-test, and the null hypothesis rejected when P <0.05
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We evaluated porphyrin synthesis from ALA and its derivatives in PAM212 and Overall, PAM212-Ras porphyrin values are higher than those observed using PAM212, for all concentration ranges and irrespective of the compound employed.
By employing longer incubation periods of 24 hr the profiles of porphyrins synthesis are similar to the 3 hr ones. With either ALA or ALA derivatives, the amount of tetrapyrroles formed from the Ras-transfected cell line is still significantly higher as compared to the parental cell line. Plateau values are obtained for all the pro-drugs and both cell lines, at higher concentrations as compared to 3 hr incubation, due to substrate consumption.
In line with the patterns of porphyrin synthesis, Figure 3 shows that the higher the amount of porphyrins, the higher the photocytotoxicity for a given dose comparing the 4 compounds within the same cell line. Overall, PAM212-Ras cells are more resistant to PDT in spite of synthesising higher amounts of porphyrins.
PDT was applied after 3 h incubation of pro-drugs at 0.01 mM, which is a plateau concentration for ALA derivatives but not for ALA. At this concentration, phototoxicity from ALA is almost negligible, whereas from all ALA derivatives the LD50s were Whereas kidney and intestine are the best porphyrins producers, the brain is the lowest. With respect to selectivity, neither of the ALA peptides gave rise to high porphyrin tumour levels relative to the skin or any other tissue. Other members of the Ras superfamily may also contribute to cancer. Proteins in the Ras family are very important molecular switches for a wide variety of signal pathways that control processes such as cytoskeletal integrity, proliferation, cell adhesion, apoptosis, and cell migration.
In our in vitro studies, the ALA derivatives did indeed prove to be more effective than ALA in PDT treatment, inducing the same porphyrin levels but at 50 to 100-fold lower concentrations. Employing a concentration of 0.01 mM, the amount of porphyrins is 2 and 3 times higher for AcLeuALAMe and AcPheALAMe respectively as compared to ALA. In addition, the performance of these peptides is even better than the best ALA ester porphryin inducer He-ALA, reaching plateau values at 5-fold lower concentrations. This improvement in porphyrin production must be due to more rapid and efficient internalization than ALA. Following illumination of cells incubated with the compounds at low concentrations (0.01 mM and 3 h exposure), LD50s were around 135 mJ/cm 2 for PAM212-Ras cells, and 45 mJ/cm 2 for PAM12 cells, whereas no cell death was induced by ALA.
In a complementary in vivo study using the mammary carcinoma cell line LM2, our results showed that topical application of the peptide prodrug AcPheALAMe is more selective than ALA, whereas systemic administration improves ALA performance, without changes on selectivity. It is worth noting that the concentrations employed for both ALA peptides, that led to tumour-photosensitising porphyrin synthesis (31) did not produce any toxic effects in mice. Through fibre optic detection of porphyrins, we have observed that after topical application, ALA induced rapid diffusion of porphyrins to other distant sites within the skin, but this was not observed for the ALA peptides.
Such a phenomenon has been previously remarked upon by us, along with a higher confinement of porphyrin synthesis from He-ALA to the application site (47). In our previous studies, a similar amount of porphyrins from ALA was synthesized in distant papillomas when compared with ALA-applied papillomas, demonstrating that either ALA itself and/or the porphyrins formed by synthesis can be distributed throughout the vasculature and accumulate in distant tumours, and though it is likely that ALA is the molecule diffusing to distant sites, we cannot discard the contribution of hydrophilic precursors of PpIX such as Uroporphyrin and Coproporphyrin.
On the other hand, lower porphyrin synthesis occurred in distant papillomas from He-ALA, showing that this ester and/or porphyrins formed from the precursor, are more selectively localized in the site of application. Similarly, when Peng et al. (48) applied ALA and other ALA esters (methyl, ethyl and propyl) to normal mouse skin they found no porphyrins using fluorescence detection in areas other than that in which the ALA ester cream was applied, while in the case of ALA, a significant fluorescence was seen in the skin outside the application area. These topically applied ALA prodrugs may be retained by stratum corneum, which may act as a reservoir (49), from which they diffuse superficially, leading to a pattern of skin porphyrin accumulation dependant on the distance from the application site.
For the novel prodrugs studied, it is possible that the ester moiety of the AcPheALAMe peptide is therefore responsible of the retention of the fluorescence to the site of application, with a greater extent of diffusion to the dermis as compared to ALA. In addition, the confinement to the site of application achieved by the use of ALA esters and ALA peptide esters, demonstrates that ALA, and not porphyrin, is the main molecule likely to be distributed through the bloodstream. This is supported by the tissue biodistribution and porphyrin extraction data, which demonstrates that both ALA and the ALA peptides are more specifically confined to the skin invaded by tumour (SOT) where the topical application was performed. As regards to biodistribution, AcPheALAMe appears to be less retained in the epidermis, but traffics to the dermis.
As has been addressed previously, the more lipohilic solutes or vehicles penetrate to a higher depth through the skin as compared to the most hydrophilic ones (Bronaugh, Dokka). This pattern of PpIX distribution correlates to the extent of photodamage after illumination. Similar histological changes were reported for both ALA and its phenylalanil peptides in terms of dermal damage and depth of tumour necrosis, though epidermal damage appears to be more subtle in ALA peptide-treated SOT.
There were no differences on SOT: tumour indexes between ALA and AcPheALAMe, however, there was indeed a selectivity of AcPheALAMe for tumour and tumour skin areas, since lower distribution to distant sites through skin and tumour vasculature was obtained. This is quite relevant, since overcoming ALA-PDT induced photosensitivity, although it lasts only for 48 h, has been addressed previously by use of protective ointments (Juzenas).
The lack of any apparent toxicity when using systemically administered ALA, is encouraging. We have also found no apparent toxicity in Wistar rats upon intravenous administration of the ALA peptides at doses of 100 mg/kg (unpublished data). On the contrary, it has been reported that ALA esters containing large alkyl chains such as ALA Hexyl ester cannot be administrated systemically due to its high toxicity. Such toxicity was ascribed to be related to the ability of lipophilic esters of ALA of crossing blood brain barrier thus inducing neurotoxicity (50) . In addition, in the mentioned work we have found that He-ALA was significantly less efficient in most tissues than ALA at producing porphyrins after i.p. administration. In the present work, we have found that 3 h after systemic administration of ALA peptides, we have obtained 1.22 ± 0.15 and 0.81 ± 0.09 µg porphyrins/g tumour tissue from AcPheALAMe and AcLeuALAMe respectively, whereas after dose equivalent of ALA Hexyl ester (50), the amount of tetrapyrroles accumulated were 0.3 ± 0.02 µg/g, value which was slightly above basal tumour levels.
It has been previously shown that AcPheALAMe and AcLeuALAMe are efficient at inducing PpIX in PAM212 cells and in pig skin explants (35, 37) . N-acetyl termination appears to play an important role in metabolic processes leading to the production of PpIX from such compounds whereas masking the C terminus as a methyl ester does not exert a major effect (36) . Using siRNA knockdown of acylpeptide hydrolase (APEH) protein expression, we were able to show the involvement of APEH, a member of the prolyl oligopeptidase family of serine peptidases, in the release of ALA from these Nacetylated peptide derivatives (36) . APEH has been shown to be expressed in various normal tissues such as erythrocytes, liver, heart, testis, intestine, kidney and brain, but its precise biological activity is unknown (51, 52, 53, 54) . In addition, peptidase expression can be different between normal and tumour cells or tissues (55) and aminopeptidase inhibitors have been designed to target tumour cells (56, 57, 58) .
In the present study, the differences between AcPheALAMe and AcLeuALAMe in vivo may be ascribed in part to a higher ability of the former to cross biological barriers such as skin lesions of the cervix, lung and brain cancer (6, 7, 8, 9, 10) . PDT can virtually be applied to any type of localized cancer which is accessible by optic fibre, and although PDT constitutes an important therapy in dermatology, the challenging delivery of ALA by using dipeptides, hampers the translation of ALA-PDT to other oncological applications.
Our results of PpIX accumulation after intraperitoneal administration suggests that systemically applied AcPheALAMe reaches every organ analysed and particularly accumulates in tumour tissue. On the other hand, our results of topical application of ALA dipeptides, highlights the ability of the Phenylalanine derivative to be confined in the area of application, cross the stratum corneum barrier, and reach the dermis and adjacent tumour tissue, with minimal dispersion to distant tissues. Due to the lack of animal skin cancer models resembling human tumour, our subcutaneous implanted tumour model is a first approach before translating the derivative to clinical applications.
In conclusion, the results in this study provide further evidence that the conjugation of ALA with specific amino acids is a promising approach for inducing enhanced intracellular porphyrin production for photodynamic therapy. 
